Supinoxin
CAS No. 888478-45-3
Supinoxin ( RX-5902 )
Catalog No. M26834 CAS No. 888478-45-3
Supinoxin is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 222 | Get Quote |
|
10MG | 335 | Get Quote |
|
25MG | 566 | Get Quote |
|
50MG | 806 | Get Quote |
|
100MG | 1098 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSupinoxin
-
NoteResearch use only, not for human use.
-
Brief DescriptionSupinoxin is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent.
-
DescriptionSupinoxin is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent. Supinoxin induces cell apoptosis and inhibits the growth of TNBC cancer cell lines (IC50s:10 nM - 20 nM).(In Vitro):Supinoxin inhibits cell growth, MDA-MB-231, Caki-1, UMRC2, PANC-1, A549, MKN-45, HepG2, HCT116, HT29, PC-3, U251, HeLa, SK-MEL-28 and OVCAR-3 (IC50: range from 0.01 μM to 0.021 μM in the growth inhibition of cancer cells). Supinoxin (0-10 μM; 72 hours) is active against cell lines of all TNBC molecular subtypes and is active against cell lines with mutations in p53, RB1, CDKN2A, and loss of PTEN. Supinoxin (20-100 nM; 24 hours) treatment causes a dose-dependent increase in tetraploid cells, consistent with induction of G2–M cell-cycle arrest. Supinoxin (0-100 nM; 24 or 48 hours) reduces MCL-1 expression in a dose-dependent manner in TNBC cell lines sensitive to Supinoxin. Supinoxin (0-100 nM; 72 hours) exhibits no significant induction of apoptosis in cell lines resistant to the antiproliferative effects of Supinoxin. But in sensitive cells, the observed activation of apoptosis begins at 24–48 hours and reaches a peak at 72 hours. The induced apoptosis is treated with a dose of 100 nM .(In Vivo):Supinoxin (p.o.; 160/320/600 mg/kg; once weekly for 3 weeks) obviously dose-dependent tumor growth inhibition in the MDA-MB-231 model, exhibits TGI of 55.7%, 80.29% and 94.58% at 160 mg/kg, 320 mg/kg and 600 mg/kg, respectively .
-
SynonymsRX-5902
-
PathwayApoptosis
-
TargetApoptosis
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number888478-45-3
-
Formula Weight441.5
-
Molecular FormulaC22H24FN5O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1cc(OC)cc(c1)N1CCN(CC1)C(=O)Nc1nc2cc(F)ccc2nc1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Omote M, et al. Acute effects of deflazacort and its metabolite 21-desacetyl-deflazacort on allergic reactions. Arzneimittelforschung. 1994 Feb;44(2):149-53.
molnova catalog
related products
-
Pivanex
Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
-
Mepazine
Mepazine is a potent and selective inhibitor of MALT1. Mepazine inhibits GSTMALT1 full length and GSTMALT1 325-760 with IC50s of 0.83 μM and 0.42 μM.
-
PDK4-IN-1 hydrochlor...
PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally active inhibitor of pyruvate dehydrogenase kinase 4 (PDK4, IC50 value = 84 nM).